Brief: Immuneonco Biopharmaceuticals Shanghai Inc Says Obtained Investigational New Drug Approval For Phase Ib/Iii Clinical Trial Of Imc-002 From Nmpa
21/06/2024 11:33
June 21 (Reuters) - ImmuneOnco Biopharmaceuticals
Shanghai Inc 1541.HK :
* OBTAINED INVESTIGATIONAL NEW DRUG APPROVAL FOR PHASE
IB/III
CLINICAL TRIAL OF IMC-002 FROM NMPA
Further company coverage: 1541.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on ImmuneOnco Biopharmaceuticals (Shanghai)
See all newsBrief: Immuneonco Biopharmaceuticals (Shanghai) To Subscribe For Wealth Management Product For Hk$87.5 Million
Brief: ImmuneOnCo Biopharmaceuticals (Shanghai) To Repurchase H Shares In Open Market
Brief: Immuneonco Biopharmaceuticals (Shanghai)Subscribes For Hk$212 Million Wealth Management Product
Brief: Immuneonco Biopharmaceuticals Shanghai Inc Posts FY Loss Attributable RMB218.6 Million
Brief: ImmuneOnco Biopharmaceuticals Shanghai Receives Approval From NMPA China For Investigational New Drug Application Of IMM0306S